Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 5, 2006, Pages 240-246

  Marier, J F ^a   Manthos, H ^a   Kebir, S ^a   Ferron, S ^a   DiMarco, M ^a   Morelli, G ^a   Tippabhotla, Sudhakar K ^b   Vijan, T ^b   Singla, A K ^b   Garg, M ^b   Monif, Tausif ^b  

^a MDS Inc   (Canada)

^b RANBAXY LABORATORIES LTD   (India)

Author keywords

Pharmacokinetics; Relative bioavailability; Zidovudine

Indexed keywords

AVIRO Z; ZIDOVUDINE;

ABDOMINAL CRAMP; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LOOSE FECES; MALE; MASS SPECTROMETRY; NAUSEA; NORMAL HUMAN; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE DRUG DOSE; SOMNOLENCE; TABLET FORMULATION; VOLUNTEER; WEAKNESS;

EID: 33646404628     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44240     Document Type: Article

References (21)

1. Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine. An update. Clin Pharmacokinet. 1996; 30: 251-262.
2. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Dekker M. Inc.; 1992.
3. Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet 1989; 17: 1-9.
4. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med. 1996; 124: 1019-1030.
5. Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, Remmel RP, Erice A, Balfour HH Jr. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther. 1998; 64: 331-338.
6. Gorsky RD, Farnham PG, Straus WL, Caldwell B, Holtgrave DR, Simonds RJ, Rogers MF, Guinan ME. Preventing perinatal transmission of HIV - costs and effectiveness of a recommended intervention. Public Health Rep. 1996; 111: 335-341.
7. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 72-78.
8. Havlir DV, Lange JM. New antiretrovirals and new combinations. AIDS. 1998; 12 (Suppl A): 165-174.
9. Lacey L, Youle M, Trueman P, Staszewski S, Schrappe M, Behrens M. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective. Pharmacoeconomics. 1999; 15 (S1): 39-53.
10. Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989; 37: 408-450.
11. Langtry RD, Palmer KJ, Benfield P. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus. Pharmacoeconomics. 1993; 3: 309-337.
12. Moore KH, Raasch RH, Brouwer KL, Opheim K, Cheeseman SH, Eyster E, Lemon SM, van der Horst CM. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrob Agents Chemother. 1995; 39: 2732-2737.
13. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004; 18: 2065-2073.
14. Robbins BL, Rodman J, McDonald C, Srinivas RV, Flynn PM, Fridland A. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother. 1994; 38: 115-121.
15. Rodman JH, Flynn PM, Robbins B, Jimenez E, Bardeguez AD, Rodriguez JF, Blanchard S, Fridland A. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. J Infect Dis. 1999; 180: 1844-1850.
16. Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE; COL30336 Study Team. Compact quadruple therapy with the lamivudine/ zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naive HIV-infected adults. HIV Clin Trials. 2003; 4: 231-243.
17. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV infection. Ann Intern Med. 1991; 114: 798-802.
18. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001; 285: 1155-1163.
19. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994; 38: 1541-1547.
20. Stringer JS, Rouse DJ. Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis. Obstet Gynecol. 1999; 94: 34-40.
21. Wilde MI, Langtry HD. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993, 46: 515-578.